Search

Experience with use of recombinant activated factor VII.

This is a case report of successfully treating hemorrhage with rFVIIa in four patients with factor VIII and one with factor V inhibitor. One patient was initially treated with APCC (Autoplex) and blood products unsuccessfully. The authors confirm the efficacy and safety of rFVIIa and suggest carrying out cost effectiveness analysis. Further information is required […]

Use of recombinant factor VII in hepatology.

This article starts with a general overview on mechanism of action, uses and safety of rFVIIa as well as the hemostatic disorders which are associated with liver disease. It states the correlation between the degree of liver damage and level and gene expression of FVII. The authors reviewed the use of rFVIIa in liver disease […]

Use of recombinant factor VIIa in hereditary bleeding disorders.

This is another excellent review of the mechanism of action, indications, and various doses of rFVIIa (Novoseven) in hereditary bleeding disorders. Its main use has been in patients with factor VIII or IX deficiency with inhibitors, where rFVIIa can by-pass factors VIII or IX, interacts with tissue factor and generates thrombin in addition to activating […]

New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate.

A very good review of inhibitors to coagulation factors, in congenital or acquired hemophilia, that covers the incidence, pathogenesis, treatment strategies (including different alternatives to human factors), and induction of immune tolerance. The article contains an algorithm approach for the management of such patients, with emphasis on the use of rFVIIa in managing hemophiliac patients […]